Historical Valuation
Fibrobiologics Inc (FBLG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.66. The fair price of Fibrobiologics Inc (FBLG) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.34
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Fibrobiologics Inc (FBLG) has a current Price-to-Book (P/B) ratio of 92.66. Compared to its 3-year average P/B ratio of 33.04 , the current P/B ratio is approximately 180.43% higher. Relative to its 5-year average P/B ratio of 33.04, the current P/B ratio is about 180.43% higher. Fibrobiologics Inc (FBLG) has a Forward Free Cash Flow (FCF) yield of approximately -104.43%. Compared to its 3-year average FCF yield of -31.83%, the current FCF yield is approximately 228.04% lower. Relative to its 5-year average FCF yield of -31.83% , the current FCF yield is about 228.04% lower.
P/B
Median3y
33.04
Median5y
33.04
FCF Yield
Median3y
-31.83
Median5y
-31.83
Competitors Valuation Multiple
AI Analysis for FBLG
The average P/S ratio for FBLG competitors is 5.22, providing a benchmark for relative valuation. Fibrobiologics Inc Corp (FBLG.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for FBLG
1Y
3Y
5Y
Market capitalization of FBLG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of FBLG in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is FBLG currently overvalued or undervalued?
Fibrobiologics Inc (FBLG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.66. The fair price of Fibrobiologics Inc (FBLG) is between to according to relative valuation methord.
What is Fibrobiologics Inc (FBLG) fair value?
FBLG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Fibrobiologics Inc (FBLG) is between to according to relative valuation methord.
How does FBLG's valuation metrics compare to the industry average?
The average P/S ratio for FBLG's competitors is 5.22, providing a benchmark for relative valuation. Fibrobiologics Inc Corp (FBLG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Fibrobiologics Inc (FBLG) as of Jan 10 2026?
As of Jan 10 2026, Fibrobiologics Inc (FBLG) has a P/B ratio of 92.66. This indicates that the market values FBLG at 92.66 times its book value.
What is the current FCF Yield for Fibrobiologics Inc (FBLG) as of Jan 10 2026?
As of Jan 10 2026, Fibrobiologics Inc (FBLG) has a FCF Yield of -104.43%. This means that for every dollar of Fibrobiologics Inc’s market capitalization, the company generates -104.43 cents in free cash flow.
What is the current Forward P/E ratio for Fibrobiologics Inc (FBLG) as of Jan 10 2026?
As of Jan 10 2026, Fibrobiologics Inc (FBLG) has a Forward P/E ratio of -0.67. This means the market is willing to pay $-0.67 for every dollar of Fibrobiologics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Fibrobiologics Inc (FBLG) as of Jan 10 2026?
As of Jan 10 2026, Fibrobiologics Inc (FBLG) has a Forward P/S ratio of 0.00. This means the market is valuing FBLG at $0.00 for every dollar of expected revenue over the next 12 months.